" class="no-js "lang="en-US"> Biomunex Pharmaceuticals - Medtech Alert
Sunday, September 28, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Biomunex Pharmaceuticals | Pharmtech Focus

Biomunex Pharmaceuticals

About Biomunex Pharmaceuticals

Biomunex Pharmaceuticals

BIOMUNEX Pharmaceuticals is a biopharmaceutical company focused on the discovery and development of breakthrough immunotherapies using its Unique BiXAb® technology to create next generation bi- and multi-specific antibodies.
Our disruptive biological approaches target a number of cancer types, in particular where there are unmet medical needs. We are committed to provide oncologists and patients with immunotherapies that are novel, efficacious and prolong life expectancy.

Related Story

Diseases

 Biomunex Unveils MAIT Cell Redirection Approach for Lead Immuno-oncology Program at PEGS Boston Conference | Pharmtech Focus

Biomunex Unveils MAIT Cell Redirection Approach for Lead Immuno-oncology Program at PEGS Boston Conference

May 4 2022

Biomunex Pharmaceuticals, a biopharmaceutical company that develops cutting-edge immunotherapies through the discovery and development of […]

Appointments

 Biomunex Appoints Dr. Simon Plyte

Biomunex Appoints Dr. Simon Plyte, PhD, as Chief Scientific Officer

April 25 2022

Biomunex Pharmaceuticals, a biopharmaceutical company that develops cutting-edge immunotherapies through the discovery and development of […]

Fundraising

 Biomunex Pharmaceuticals’ Breakthrough Immunotherapy Project Receives Grants Close to €3 Million | Pharmtech Focus

Biomunex Pharmaceuticals’ Breakthrough Immunotherapy Project Receives Grants Close to €3 Million

November 3 2021

Biomunex Pharmaceuticals, a biopharmaceutical company that develops cutting-edge immunotherapy through the discovery and development of bi- and multi-specific […]